This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
HealthdirectFree Australian health advice you can count on.
INN: bimekizumab
Data updated: 2026-04-25
Available in:
🇨🇿🇬🇧🇫🇷🇸🇰
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
UCB Pharma S.A.
ATC Code
L04AC21
Source
EMA · EMEA/H/C/005316
(
ARTG
)
Plaque Psoriasis
Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,Psoriatic arthritis
Bimzelx is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response to or who have been intolerant to previous disease modifying antirheumatic drug (DMARD) therapy.,Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSpA)
Bimzelx is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI) who have had an inadequate response to or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
Bimzelx is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.,Hidradenitis suppurativa (HS)
Bimzelx is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic HS therapy.